Evaluation of Retinal and Vascular Features in Coats Disease After Intravitreal Injections of Ranibizumab

Sponsor
Federico II University
Study ID
NCT04310631
Status
Completed

Conditions

  • Coats Disease

Eligibility Criteria

Sex
MALE
Age
19 Years - 30 Years
Healthy Volunteers
Not accepted

Interventions

  • Ranibizumab Injection — DRUG
    Ranibizumab Injection (0.5 mg/0.05 ml): Three monthly intravitreal injections

Study Details

This study evaluates the retinal and vascular features in patients affected by Coats disease under the effects of Ranibizumab intravitreal injections using optical coherence tomography and optical coherence tomography angiography

Key Dates

First listed
Mar 17, 2020
Start date
Jan 1, 2016
Status verified
Mar 2020
Primary completion
Dec 31, 2019
Completion
Dec 31, 2019

Study Design

Enrollment
5 participants (actual)

Primary Outcome Measure

Study of retinal and vascular features in Coats disease after intravitreal injections of Ranibizumab [ Time Frame: Three months ]